BACE1 and Alzheimer disease: These data, along with the fact that both the activity and the expression pattern of BACE1 are elevated in human sporadic AD patients 13, 14, provide a conceptual basis for a BACE1‐dependent mechanism of Aβ accumulation and suggest BACE1 as a primary drug target for AD therapy 10.